These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 29045188

  • 1. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ.
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A, Kottschade L, Ryder M.
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
    de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B.
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
    [Abstract] [Full Text] [Related]

  • 6. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 7. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
    Pollack RM, Kagan M, Lotem M, Dresner-Pollak R.
    Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
    [Abstract] [Full Text] [Related]

  • 8. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.
    Alhusseini M, Samantray J.
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):267-269. PubMed ID: 28073132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
    Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM.
    Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
    Zhang X, Wu Y, Lv J, Li X, Ma L, Nong J, Zhang H, Qin N, Zhang Q, Shi G, Yang X, Wang J, Zhang S.
    Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
    Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2770-2780. PubMed ID: 28609832
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N.
    PLoS One; 2019 Aug 01; 14(5):e0216954. PubMed ID: 31086392
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M.
    J Endocrinol Invest; 2019 Dec 01; 42(12):1443-1450. PubMed ID: 31093955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.